These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21288851)

  • 1. Impact of antiretroviral therapy on HIV-related brain injury.
    Price RW
    Clin Infect Dis; 2011 Jan; 52(2):244-7. PubMed ID: 21288851
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefit or toxicity from neurologically targeted antiretroviral therapy?
    Brew BJ
    Clin Infect Dis; 2010 Mar; 50(6):930-2. PubMed ID: 20146628
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment".
    Garvey L; Thomson EC; Main J; Winston A
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):656-7, author reply 657-8. PubMed ID: 18043322
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-associated central nervous system diseases in the era of combination antiretroviral therapy.
    Tan IL; McArthur JC
    Eur J Neurol; 2011 Mar; 18(3):371-2. PubMed ID: 21159069
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV-associated dementia in the era of highly active antiretroviral therapy (HAART).
    Xia C; Luo D; Yu X; Jiang S; Liu S
    Microbes Infect; 2011 May; 13(5):419-25. PubMed ID: 21262373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic Improvement of MRI Abnormalities of HIV Encephalopathy after Suppressive Antiretroviral Therapy.
    Dietrich DK; Laidlaw E; Hammoud DA; Pau AK; Smith BR
    AIDS; 2023 Jul; 37(8):1339-1340. PubMed ID: 37771854
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy recommendations for HIV-associated neurocognitive disorders.
    Zirulnik JL
    JAMA; 2008 Dec; 300(21):2482; author reply 2482-3. PubMed ID: 19050186
    [No Abstract]   [Full Text] [Related]  

  • 8. Changing patterns in the neuropathogenesis of HIV during the HAART era.
    Langford TD; Letendre SL; Larrea GJ; Masliah E
    Brain Pathol; 2003 Apr; 13(2):195-210. PubMed ID: 12744473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive impairment and neuroCART.
    Wright E
    Curr Opin HIV AIDS; 2011 Jul; 6(4):303-8. PubMed ID: 21546833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
    Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K
    Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the efficacy of highly active antiretroviral therapy in the brain.
    Kandanearatchi A; Williams B; Everall IP
    Brain Pathol; 2003 Jan; 13(1):104-10. PubMed ID: 12580550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
    Sharma I
    HIV Med; 2021 Oct; 22(9):783-790. PubMed ID: 34291558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
    Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA;
    Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV encephalitis in a patient on antiretroviral therapy: a case report.
    Hlebowicz M; Parczewski M; Jakubowski P
    Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.
    Neuenburg JK; Brodt HR; Herndier BG; Bickel M; Bacchetti P; Price RW; Grant RM; Schlote W
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):171-7. PubMed ID: 12394795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.
    Beardsley J; Le T
    Neurology; 2015 Feb; 84(6):632. PubMed ID: 25666633
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence of Neurological Disorders Among HIV-Infected Individuals With Universal Health Care in Taiwan From 2000 to 2010.
    Tsai YT; Chen YC; Hsieh CY; Ko WC; Ko NY
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):509-516. PubMed ID: 28520614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of current antiretroviral therapies on neuroAIDS.
    Vivithanaporn P; Gill MJ; Power C
    Expert Rev Anti Infect Ther; 2011 Apr; 9(4):371-4. PubMed ID: 21504390
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV-associated neurocognitive disorders: perspective on management strategies.
    Nabha L; Duong L; Timpone J
    Drugs; 2013 Jun; 73(9):893-905. PubMed ID: 23733447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.